Volume 22, Number 12—December 2016
Letter
Zika Virus Infection in the Central Nervous System and Female Genital Tract
Table
Test/specimen type |
1st sample, day 6† |
2nd sample, day 7† |
3rd sample, day 10† |
4th sample, day 13† |
5th sample, day 17† |
6th sample, day 28† |
---|---|---|---|---|---|---|
Zika virus | ||||||
rRT-PCR‡ serum | Positive (32.9) | Negative | Negative | Negative | Negative | Negative |
rRT-PCR‡ urine | Positive (34.2) | Positive (31.8) | Positive (32.4) | Positive (29.8) | Positive (32.1) | Positive (32.2) |
rRT-PCR‡ saliva | ND | Positive (29.9) | Positive (33.5) | Positive (34.1) | Negative | Negative |
rRT-PCR‡ CSF | ND | Positive (37.0) | ND | ND | Negative | ND |
rRT-PCR‡ cervical swab sample | ND | Positive (31.1) | Negative | Positive (34.3) | Negative | Negative |
IFA§ IgM titer | <1:20 | 1:40 | 1:160 | 1:80 | 1:320 | 1:1,280 |
IFA§ IgG titer | <1:20 | <1:20 | 1:40 | 1:320 | 1:320 | 1:320 |
MNT¶ Ab titer |
ND |
ND |
1:40 |
ND |
1:160 |
>1:640 |
Dengue virus IFA§ IgM titer | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 |
Dengue virus IFA§ IgG titer |
<1:20 |
<1:20 |
<1:20 |
<1:20 |
<1:20 |
<1:20 |
Chikungunya virus IFA§ IgM titer | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 |
Chikungunya virus IFA§ IgG titer | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 |
*Ab, antibody; CSF, cerebrospinal fluid; IFA, immunofluorescence assay; MNT, microneutralization test; ND, not done; rRT-PCR, real-time reverse transcription PCR.
†Days from symptom onset.
‡Zika virus–specific rRT-PCR (RealStar Zika Virus RT-PCR Kit 1.0; Altona Diagnostics GmbH; Hamburg, Germany). Numbers in parentheses indicate cycle threshold values (Technical Appendix).
§IgG and IgM IFA (Arbovirus Mosaic 2; Euroimmun AG; Luebeck, Germany). Reference values (titer) serum: <1:20 = negative; >1:20 = positive (Technical Appendix).
¶MNT titers <1:20 were considered negative (Technical Appendix).
Page created: November 18, 2016
Page updated: November 18, 2016
Page reviewed: November 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.